Literature DB >> 35402202

Multidisciplinary treatment of pancreatic cancer: a case report.

Xing-Ru Wang1, Lin-Xia Nie2, Xiang-Hong Guo1, Tian-Xi Liu1, Xiao-Ju Li1, Hong-Yu Zhang2, Heng Lin2.   

Abstract

Background: Carcinoma of the head of pancreas has a high malignant degree and the 5-year survival rate at 5%. For unresectable pancreatic cancer, the 5-year survival rate is even lower. The clinical diagnosis of pancreatic cancer is difficult, and surgical indications are difficult to grasp. Moreover, perioperative and postoperative management is complex, and patients with different conditions need more attention to implement a comprehensive diagnosis and treatment strategy. In the diagnosis and treatment of pancreatic cancer and even other cancers, multi-disciplinary diagnosis and treatment can provide reasonable, personalized and more effective plans for patients so that cancer patients can receive better treatment and improve their quality of life. The multi-disciplinary diagnosis and treatment model can respond to the complex needs to individual patients. Case Description: This model is designed according to each patient's comprehensive situation, including their clinical symptoms, biochemical indicators, body mass index, and psychological status, and the tumor position, pathological tissue typing, and invasion scope. Complications of tumors can be reduced if treatment is controlled and if radical treatments are used within a broader comprehensive care model, thereby improving the quality of life of patients to prolong their survival. In our case report, the overall survival is much longer than un-resectable pancreatic cancer (median overall survival 6-9 months. The female patient was 53 years old. Her chief complaints were yellow skin, yellow urine, and absorption emaciation for 1 month. The preliminary diagnosis was postoperative pancreatic cancer. CT reexamination suggested portal vein liver metastasis. Repeated gastrointestinal bleeding occurs over the course of the disease. Postoperative review suggested recurrence, and she was admitted to First Affiliated Hospital, Army Medical University. During the treatment, the disease progressed to gastrointestinal bleeding, ascites, and jaundice. Conclusions: After multidisciplinary treatment (MDT) discussion, targeted treatment strategies were developed to improve the symptoms and improve the quality of life of the patients. 2022 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Multidisciplinary treatment (MDT); case report; pancreatic cancer; post operation

Year:  2022        PMID: 35402202      PMCID: PMC8984991          DOI: 10.21037/gs-22-86

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  8 in total

1.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

3.  Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

Authors:  Hideki Ueno; Tatsuya Ioka; Masafumi Ikeda; Shinichi Ohkawa; Hiroaki Yanagimoto; Narikazu Boku; Akira Fukutomi; Kazuya Sugimori; Hideo Baba; Kenji Yamao; Tomotaka Shimamura; Masayuki Sho; Masayuki Kitano; Ann-Lii Cheng; Kazuhiro Mizumoto; Jen-Shi Chen; Junji Furuse; Akihiro Funakoshi; Takashi Hatori; Taketo Yamaguchi; Shinichi Egawa; Atsushi Sato; Yasuo Ohashi; Takuji Okusaka; Masao Tanaka
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

Review 4.  Pancreatic cancer.

Authors:  Audrey Vincent; Joseph Herman; Rich Schulick; Ralph H Hruban; Michael Goggins
Journal:  Lancet       Date:  2011-05-26       Impact factor: 79.321

Review 5.  Pancreatic cancer.

Authors:  Donghui Li; Keping Xie; Robert Wolff; James L Abbruzzese
Journal:  Lancet       Date:  2004-03-27       Impact factor: 79.321

6.  Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma.

Authors:  Quyen D Chu; Meijiao Zhou; Prakash Peddi; Kaelen L Medeiros; Gazi B Zibari; Hosein Shokouh-Amiri; Xiao-Cheng Wu
Journal:  HPB (Oxford)       Date:  2017-09-28       Impact factor: 3.647

7.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

Review 8.  Treatment optimization of locally advanced and metastatic pancreatic cancer (Review).

Authors:  Anabela G Barros; Catarina F Pulido; Manuela Machado; Maria José Brito; Nuno Couto; Olga Sousa; Sónia A Melo; Hélder Mansinho
Journal:  Int J Oncol       Date:  2021-12-03       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.